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Abstract
Purine homeostasis is ensured through a metabolic network widely conserved from 
prokaryotes to humans. Purines can either be synthesized de novo, reused, or produced 
by interconversion of extant metabolites using the so-called recycling pathway. Although 
thoroughly characterized in microorganisms, such as yeast or bacteria, little is known 
about the regulation of the purine biosynthesis network in metazoans. In humans, several 
diseases are linked to purine metabolism through yet poorly understood etiologies. 
Particularly, the deficiency in Adenylosuccinate Lyase (ADSL), one enzyme involved both 
in the purine de novo and recycling pathways, causes severe muscular and neuronal 
symptoms. In order to address the mechanisms underlying this deficiency, we established 
Caenorhabditis elegans as a metazoan model organism to study purine metabolism, while 
focusing on ADSL. We show that the purine biosynthesis network is functionally conserved 
in C. elegans. Moreover, adsl-1 (the gene encoding ADSL in C. elegans) is required for 
developmental timing, germline stem cell maintenance and muscle integrity. Importantly, 
these traits are not affected when sole the de novo pathway is abolished, and we present 
evidence that germline maintenance is linked specifically to the ADSL activity in the 
recycling pathway. Hence, our results allow to ascribe developmental and tissue specific 
phenotypes to separable steps of the purine metabolic network in an animal model.
Introduction
Purine biosynthesis pathways ensure the production and homeostasis of AMP and 
GMP in the cell, and are widely conserved throughout evolution. The de novo pathway 
leads to the synthesis of IMP (Inosine monophosphate) using PRPP (5-Phosphoribosyl-1-
pyrophosphate) as precursor. The recycling pathway (a.k.a. salvage pathway) can then 
transform extant purines, including IMP synthesized through the de novo pathway, to 
produce AMP and GMP (Figure 1A; reviewed in Ljungdahl and Daignan-Fornier, 2012). 
Importantly, if available in the extracellular environment, purines can be recovered by 
specific transporters and subsequently be metabolized through the recycling pathway, 
which requires much less energy expenditure. Indeed, purine synthesis through the de 
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novo pathway requires the hydrolysis of six more molecules of ATP than purine synthesis 
through the recycling pathway.
Imbalance in purine metabolism is involved in several diseases that have been 
extensively characterized, most of them associated with mutations in genes encoding for 
purine biosynthesis enzymes (reviewed in Nyhan 2005; Kelley and Andersson 2014). The 
genetics and biochemistry of purine biosynthesis are well established in unicellular 
organisms like bacteria or yeast, and are highly conserved. Nonetheless, how the disease-
causing enzymatic deficiencies lead to the symptoms observed in patients remains 
elusive. It is particularly challenging to untangle the contribution of shortage in the final 
products - AMP and GMP - from mutation-caused accumulation of intermediate 
metabolites in the pathway. For instance, ZMP (5-amino-4-imidazole carboxamide 
ribonucleotide monophosphate; Bochner and Ames, 1982) and SZMP (succinyl-ZMP), two 
intermediates of the purine de novo pathway (Figure 1), are known to act as signal 
metabolites regulating gene expression transcriptionally in yeast (Pinson et al. 2009). 
Moreover, ZMP is known to activate AMPK (AMP activated kinase) by mimicking AMP (Jin 
et al. 2007) and SZMP has been shown to directly bind and interfere with pyruvate kinase 
activity in cancer cells (Keller et al. 2012). In addition, SAMP (succinyl-AMP), an 
intermediate metabolite in the recycling pathway, has been shown to stimulate Insulin 
secretion in pancreatic cells (Gooding et al. 2015). Hence SZMP, ZMP or SAMP buildup 
could potentially disrupt homeostasis upon deficiencies in the enzymes using them as 
substrates - ADSL (SZMP and SAMP) and ATIC (ZMP, Figure 1A). Accordingly, mutations 
in the human genes encoding for these two enzymes are associated with ADSL deficiency 
and ATIC deficiency (a.k.a. AICAribosiduria), syndromes whose etiology remains unknown 
(Race et al. 2000; Marie et al. 2004; Spiegel et al. 2006; Jurecka et al. 2008; Zikanova et 
al. 2010; Jurecka et al. 2015). Adding to the complexity of the issue, ADSL catalyzes two 
different reactions, conversion of SZMP in ZMP in the de novo pathway, and conversion of 
SAMP in AMP, a step required for AMP synthesis whether it’s from the de novo or from the 
recycling pathway (Figure 1A). This raises the question of which of the two steps is 
associated with ADSL deficiency phenotypes.
The study of purine metabolic deficiencies in patients, faces yet other challenges, in 
comparison with microorganisms. One such challenge is tissue specificity, as different 
tissues may require different levels of purines, depending on their specialized function. For 
instance, in ADSL-deficiency patients, the most severe symptoms affect the muscles and 
the nervous system, suggesting these tissues have a larger requirement for purine 
metabolism, either for their function or during development. Another challenge is purine 
transport across tissues; the tissue affected by the deficiency not being necessarily the 
tissue where the enzyme is active. Moreover, purines can be available exogenously from 
the food source, therefore the consequences of purine metabolism deficiencies are not 
necessarily caused by limiting amounts of purines. Finally, purine metabolism might be 
subject to different regulations throughout development, in which case the impairments 
observed could be the consequence of a requirement for purine regulation at a specific 
developmental stage.
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In order to address these issues, we sought to take advantage of C. elegans as 
model organism. Through a genetic approach, we characterized deficiencies in the purine 
biosynthesis pathways, focusing our analysis on an ADSL deficient mutant. Our goal was 
to establish the phenotypes associated with this enzymatic deficiency in order to uncover 
what functions, tissues and developmental stages are affected. Given ADSL is required 
both in the de novo and recycling pathways, we performed a comparative analysis with 
ATIC and GPPAT deficiencies to dissect the contribution of the de novo vs. recycling 
pathways to the phenotypes observed. We established that ADSL deficiency strongly 
disrupts muscle integrity, post-embryonic developmental timing and germline stem cells 
(GSCs) maintenance. Importantly, neither abolishing the de novo purine synthesis 
pathway per se, nor the accumulation of de novo pathway intermediate metabolites ZMP 
and SZMP, has an impact on these traits. Furthermore, we found no essential requirement 
for the de novo pathway in C. elegans under standard laboratory conditions.
Materials and Methods
- Caenorhabditis elegans strains and culture
Nematodes were maintained under standard culture conditions (Brenner, 1974; Stiernagle, 
2006), on nematode growth medium (NGM), with Escherichia Coli (strain OP50) as food 
source, kept at 20°C (except strains carrying the transgene ruIs32 [pie-1p::GFP::H2B + 
unc-119(+)], which were kept at 25°C). 
The following Caenorhabditis elegans strains were used in the study: N2 (Bristol, wild-type 
reference strain) obtained from the Caenorhabditis Genetics Center (CGC), AZ212 ruIs32 
[pie-1p::GFP::H2B + unc-119(+)] III, CF1903 glp-1(e2141) III, PE254 feIs4 
[sur-5p::luciferase::GFP + rol-6(su1006)] V, VC2999 R151.2(gk3067) III/hT2 [bli-4(e937) 
let-?(q782) qIs48] (I,III) - parental strain for the hT2 balancer, WBX52 adsl-1(tm3328) I/hT2 
[bli-4(e937) let-?(q782) qIs48] (I,III), WBX53 adsl-1(tm3328) I; ppat-1(tm6344) III/hT2 
[bli-4(e937) let-?(q782) qIs48] ppat-1(tm6344) (I,III) (from WBX119 and WBX52), WBX116 
ppat-1(tm6344) III, WBX119 ppat-1(tm6344) III, WBX117 atic-1(tm6374) IV, atic-1(tm6374) 
IV (from WBX119 and WBX117); WBX124 atic-1(tm6374) IV; feIs4 [sur-5p::luciferase::GFP 
+ rol-6(su1006)] V (from PE254 and WBX116), WBX127 ppat-1(tm6344) I; adsl-1(tm3328) 
III/hT2 [bli-4(e937) let-?(q782) qIs48] ppat-1(tm6344) (I,III); feIs4 [sur-5p::luciferase::GFP + 
rol-6(su1006)] V (from PE254 and WBX53), WBX125 ppat-1(tm6344) III; atic-1(tm6374) 
IV; feIs4 [sur-5p::luciferase::GFP + rol-6(su1006)] V (from PE254 and WBX116), WBX130 
adsl-1(tm3328) I/hT2 [bli-4(e937) let-?(q782) qIs48] (I,III); feIs4 [sur-5p::luciferase::GFP + 
rol-6(su1006)] V (PE254 and WBX53), WBX131 ppat-1(tm6344) III; feIs4 
[sur-5p::luciferase::GFP + rol-6(su1006)] V (from PE254 and WBX116), WBX147 
ppat-1(tm6344) ruIs32 [pie-1p::GFP::H2B + unc-119(+)] III (from AZ212 and WBX119), 
WBX149 adsl-1(tm3328) I; ruIs32 [pie-1p::GFP::H2B + unc-119(+)] III/hT2 [bli-4(e937) 
let-?(q782) qIs48] (I,III) (from AZ212 and WBX52) and WBX152 adsl-1(tm3328) I; 
ppat-1(tm6344) ruIs32 [pie-1p::GFP::H2B + unc-119(+)] III/hT2 [bli-4(e937) let-?(q782) 
qIs48] (I,III) (from WBX147 and WBX149). The adsl-1(tm3328), ppat-1(tm6344) and 
atic-1(tm6374) deletion alleles - referred to as adsl-1(∆), ppat-1(∆) and atic-1(∆) throughout 
the manuscript - were generated by the lab of Dr. Shohei Mitani, National Bioresource 
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Project, Japan (NBRP), all strains carrying these alleles used in this study were 
outcrossed a minimum of four times.
Nematode synchronization: Adult worms were collected with M9 buffer in 15 ml conical 
tubes, centrifuged 1 min at 1000 rpm and supernatant was discarded. Worm bleach 
solution (NaOH 1 M, NaOCl 0.25 M) was added until carcasses dissolve and eggs release 
(~8 min). Eggs were washed three times with M9 buffer transferred onto NGM seeded 
plates.
R N A i : a d s l - 1 P C R f r a g m e n t w a s a m p l i fi e d w i t h o l i g o m e r s 5 ’ -
CTTCTTCCGGCAGAATCATCCAGTG-3’ and 5’-TGACTGTCGGACGTACTCATTACC-3’, 
a n d a d s s - 1 P C R f r a g m e n t w a s a m p l i fi e d w i t h o l i g o m e r s 5 ’ -
GACGTCTTCCAACAAGACTGTGTCC-3’ and 5’-ACGAGACGGCGATACTTCTCCGAG-3’. 
Both fragments were inserted onto L4440 plasmid (EcoRV site) (Timmons and Fire 1998). 
For RNAi experiments, HT115(DE3) bacteria transformed with either the adsl-1(RNAi) or 
adss-1(RNAi) feeding vectors, or L4440 plasmid (Control), were cultured overnight at 37°C 
in LB 150 mg/L Ampicillin and induced with 2 mM IPTG 1-2 h prior seeding onto NGM 2 
mM IPTG 150 mg/L Ampicillin, in which synchronous populations of worms were cultured 
from hatching to adulthood (unless specified).
Embryonic lethality in adsl-1(tm338)/+ progeny: adsl-1(tm338)/hT2 [bli-4(e937) let-?(q782) 
qIs48] hermaphrodites - expressing pharyngeal GFP - were crossed to N2 males, non-
GFP hermaphrodites in the progeny were selected as adsl-1(tm338)/+ and allowed to lay 
eggs, one worm per plate, for ~24h. Upon removal of the adults plates were kept in culture 
for another 24h, upon which unhatched eggs were scored as dead embryos.
- Yeast heterologous rescue assay
Yeast expression vectors were constructed by inserting full length cDNAs of ppat-1 
( a m p l i fi e d u s i n g o l i g o m e r s 5 ’ -
CACTAAATTACCGGATCAATTCGGGGGATCCATGTGTGGTATATTTGGGATTG-3’ and 5’-
CATAACTAATTACATGATGCGGCCCTCCTGCAGTTATAAATCGATAGCAACTGG-3’), 
a d s l - 1 ( 5 ’ - C G G G AT C C G TAT C AT G G C C T C C G A A G A C A A G T- 3 ’ a n d 5 ’ -
CCAATGCATGAATCAAACATCCAGCTGAACATTTCC-3 ’ ) and at ic -1b (5 ’ -
G A A G A T C T C G A C G A A T T G T G T G A A A T G A C C G A C - 3 ’ a n d 5 ’ -
ATAAGAATGCGGCCGCATCTAATGGTGGAAGAGACGAAGTC-3’) onto pCM189 plasmid 
(Gari et al. 1997). ade4∆ yeast strain, genotype ade4::KanMX4; his3∆1; leu2∆0; lys2∆0; 
ura3∆0, was used to test heterologous rescue by ppat-1, ade13∆ yeast strain, genotype 
ade13::kanMX4; his3∆; leu2∆; ura3∆, was used to test heterologous rescue by adsl-1 and 
ade16∆ ade17∆ double mutant, genotype ade16::KanMX4; ade17::KanMX4; his3∆1; 
leu2∆0; ura3∆0; lys2∆0 was used to test heterologous rescue with atic-1b.
- adsl-1(∆) rescue
A genomic fragment containing the adsl-1 reference allele, ~1Kb upstream the start codon 
and ~1Kb downstream the stop codon, was amplified by PCR using oligonucleotides 5’-
GCTCCCATGATATTCTACCG-3’ and 5’-GAGGATTCAACGGTGCTTGCA-3’, and as 
template the cosmid R06C7 (obtained from the Sanger Center). The PCR amplified 
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fragment was cloned onto pBluescript on the EcoRV site, we named this plasmid pRM01. 
The insert sequence was verified upon cloning. Transgenic lines were obtained by 
standard microinjection (Mello et al. 1991), adsl-1/+ animals were co-transformed with 
pRM01 at 1ng/µl or 5ng/µl, pDD04 at 10ng/µl as transformation marker - pDD04 expresses 
GFP in tha pharynx, under the control of the myo-2 promotor (Giordano-Santini et al. 
2010) and pJM001 as carrier DNA at 30-90ng/µl (kind gift by Denis Dupuy, unpublished).
- Imaging
For adult morphology, DIC (Differential Interference Contrast, a.k.a. Nomarski) images 
were taken with a Leitz Diaplan microscope. Adult worms were mounted in M9 buffer, on 
2% agarose cushion. Images were acquired with VisiCam 5.0 camera, analyzed and 
processed with Fiji software. For imaging of pie-1p::GFP::H2B germline reporter, 
synchronized adult worms were mounted in M9 Buffer 5 mM Levamisole onto 2% agarose 
cushion. Images were acquired with an Olympus IX81 microscope under an 40X oil-
immersion objective, with Hamamatsu Orca R2 camera. Images were analyzed with Fiji 
software. For size measurements synchronized populations of young adult worms were 
used, each worm was measured 3 times on three different pictures. Images were acquired 
on a Nikon SMZ18 stereo microscope with VisiCam 5.0 camera, analyzed and processed 
with Fiji software.
- Immunostainings
Immunostaining was performed on synchronized populations of worms, N2 and de novo 
pathway mutants were fixed 72 h after synchronization, adsl-1(∆) and ppat-1(∆); adsl-1(∆) 
were fixed 96h after synchronization. Fixation protocol was adapted from Benian et al. 
(Benian et al. 1996). Worms were collected in ice cold PBS buffer on 1.5 ml tubes, 
centrifuged and supernatant was discarded, and fixation solution was added (made fresh, 
1ml of MRBW buffer KCl 320 mM, NaCl 80 mM, EGTA 40 mM, Spermidine 20 mM, Pipes 
60 mM was added to 2.8 ml of Methanol and 200 µl of Formaldehyde 20%), followed by 
five cycles of freezing in liquid N2 and thawing and 1 h incubation at 4°C with gentle 
agitation, fixation solution was replaced by a permeabilization solution (PBS, Triton X-100 
2%, ß-mercapto-ethanol 1%) and incubated 1h at room temperature, permeabilization 
solution was renewed and incubated 1h at room temperature, followed by three washes in 
PBSt (PBS, Triton X-100 0.5%), after which worms were incubated with primary antibody 
(diluted 1:1000 in PBSt 5% Fetal Calf Serum) overnight at 4°C with gentle agitation, 
washed three times in PBSt and incubated with secondary antibody (diluted 1:500 in PBSt 
5%FCS). Monoclonal antibody 5-6 (Developmental Studies Hybridoma Bank) directed 
against muscle myosin was used as primary antibody, anti-mouse Alexa555 (Molecular 
Probes) was used as secondary antibody, worms were mounted on Fluoroshield (Sigma). 
Images were acquired with a Leica DM6000 TCS SP5 confocal microscope using LAS AF 
(Leica) software.
- Metabolic profiling by HPLC
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For an extraction, ~7500 young adult worms, 72 h after synchronization, were collected 
with ice cold water, onto 15 ml conical tubes, and centrifuged at 1000 rpm, 1 min and 4°C, 
supernatant was discarded eliminating most bacteria. The nematode pellet was washed 
with 10 ml of cold Hepes 10 mM and centrifuged. The worm pellet was resuspended in 
Hepes 10 mM, 1 ml of worm suspension is transferred onto 4 ml of absolute ethanol at 
80°C, incubated for 5 min and cooled on ice for 10 min. Samples were desiccated on a 
rotovapor apparatus, the dry residue was resuspended in 350 µl of HyClone Molecular 
Biology-Grade Water (GE Healthcare) and centrifuged at 21000 g, 5 min at 4°C, 
supernatant was transferred and centrifuged again at 21000 g, 1 h at 4°C. The last 
supernatant was used for HPLC. Metabolites were separated by ionic chromatography on 
an ICS3000 chromatography station (Dionex, Sunnyvale, CA), and measured by an UV 
diode array (Ultimate 3000 RS, Dionex). Metabolites separation was done on a 
carbopacPA1 column (250 × 2 mm; Dionex) using a sodium acetate gradient (Ceballos-
Picot et al. 2015). Metabolite levels were normalized relative to dry weight; the same 
amount of worms used in the extractions were collected in ice cold water, 72h after 
synchronization, centrifuged, washed 5 times with water, allowed to evaporate for 4 days 
at 70°C and weighed.
- Lifespan
Upon synchronization (see above), worms were grown on standard conditions until reach 
adulthood, upon which they transferred onto a new plate every 24 h, and scored. Immobile 
worms unresponsive to touch were considered dead. Three replicate experiments were 
performed on different days, typically with three different plates per genotype, per replicate 
and 10-40 worms per plate.
- Locomotion and Behavioral assays
Locomotion speed measurement was adapted from (Zheng et al. 1999; Hart, 2006); 
images were acquired on a Leica Z16 APO Macroscope and processed with Fiji software. 
Worm displacement was measured by tracking the anterior pharynx position, once per 
second. For each recording one single worm was placed on one intermediate plate without 
food, than transferred onto the recorded plate ~0,5cm away from the bacterial food source 
with the pharynx towards the bacteria lawn. Locomotion was recorded for one minute, or 
until the worm reached the bacteria if it did so in less than one minute.
Aldicarb (Sigma) and levamisole (Sigma) assays were performed as described in (Gendrel 
et al. 2009), synchronized adult worms were placed on 1 mM Aldicarb or 0.4 mM 
Levamisole plates for 2 h, after which plates were tapped 10 times and worm movement 
was scored. 
Mechanosensory response assay was performed as described in (Hobert et al. 1999; Hart, 
2006), adult worms (~72h after synchronization) were isolated on plates without food for 3 
min, and stimulated with an eyelash on the posterior pharynx, and scored for avoidance 
behavior, each worm was stimulated and score 10 times 3 minutes apart.
- Post embryonic development
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Monitoring of post-embryonic development was performed as described by Olmedo et al. 
(Olmedo et al. 2015). In brief, upon synchronization, 20 embryos per µl were incubated in 
M9 buffer overnight with agitation, allowing L1 larvae to hatch. A single L1 larvae was 
added per well in 96-well plates with S-Basal media, 10 g/L E. coli OP50 (wet weight) and 
100 µM D-Luciferin. The luminescence was measured with a Berthold Centro LB960 XS3 
during 1 second at 5-min intervals, within a temperature controlled Panasonic MIR-154 
incubator.
- Statistics
Statistical analysis was done using Graphpad, Excel, Numbers and R softwares. We 
consider statistical test to be significant when pValue <0.01.
Strains and plasmids are available upon request. The authors affirm that all data 
necessary for confirming the conclusions of the article are present within the article, 
figures, and tables.
Results
- Purine biosynthesis pathway is functionally conserved in C. elegans
In order to establish C. elegans as a model to study purine metabolism, we first 
sought to investigate the conservation of the purine biosynthesis network. We identified, 
through sequence homology, genes encoding the putative nematode enzymes involved in 
purine biosynthesis (Figure S1A). We found that both de novo and recycling pathways are 
conserved in C. elegans, judged by sequence similarity. Specifically, for each enzyme we 
identified one single orthologue, in all but one case (three genes putatively encoding 
Xanthine Oxidase). Noteworthy, in S. cerevisiae the histidine pathway contributes to the 
purine de novo pathway, ZMP being a byproduct of histidine synthesis (reviewed in 
Ljungdahl and Daignan-Fornier, 2012). We have found no C. elegans orthologues for 
yeast HIS1, HIS4, HIS6 and HIS7 - required for ZMP synthesis through the histidine 
pathway - consistent with the histidine pathway loss in worms previously reported (Payne 
and Loomis, 2006), thus ZMP is most likely synthesized exclusively through the purine de 
novo pathway.
Given the sequence conservation, we undertook a functional analysis focusing on 
the ADSL enzyme, and including ATIC and GPPAT for comparison (see below). 
Importantly, sequence alignment showed that ADSL, ATIC and GPPAT are highly 
conserved (Figure S2). The genes encoding ADSL, ATIC and GPPAT in C. elegans were 
named respectively adsl-1, atic-1 and ppat-1 (wormbase.org). We first tested whether 
those three C. elegans genes were functionally conserved using an heterologous rescue 
assay. We transformed yeast Saccharomyces cerevisiae ade13∆, ade16∆ ade17∆ and 
ade4∆ mutants with plasmids containing the wild-type sequences of the predicted C. 
elegans homologous genes: adsl-1, atic-1 and ppat-1, respectively. Expression of adsl-1 
restored adenine prototrophy of ade13∆ yeast (Figure 1B), likewise expression of splicing 
isoform atic-1b restored adenine prototrophy of ade16∆ade17∆ double mutant (Figure 1B). 
These results confirm adsl-1 encodes the ADSL enzyme and atic-1 encodes for the ATIC 
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enzyme. By contrast, expression of ppat-1 alone was not sufficient to restore adenine 
prototrophy of yeast ade4∆ (Figure 1B), thus in our heterologous rescue assay we could 
neither confirm nor rule out ppat-1 encodes the GPPAT enzyme.
We next tested functional conservation of ADSL, ATIC and GPPAT activities in vivo. 
For our functional analysis, we used deletion mutant alleles, putative genetic nulls, 
henceforth referred to as adsl-1(∆), atic-1(∆) and ppat-1(∆) (see Materials and Methods). 
One would predict accumulation of ADSL substrates SZMP and SAMP upon adsl-1 loss-
of-function as well as ZMP buildup in atic-1(∆), and no detectable de novo pathway 
intermediate metabolites in ppat-1(∆) (Figure S1B). To test these hypotheses, we 
performed worm metabolic profiling by HPLC (Figure S1C). We observed a consistent 
accumulation of SZMP and its riboside form SAICAR upon adsl-1(RNAi), as well as a 
robust accumulation of SAMP, and its riboside form SAdo (Figure 1C), while neither 
metabolite was detected in the wild-type (N2) reference strain. Hence both de novo and 
recycling pathways are functionally conserved in C. elegans, and adsl-1 is required for 
ADSL activity in vivo. Furthermore, we observe a modest but consistent accumulation of 
ZMP both in atic-1(∆) mutants (Figure 1D), as well as atic-1(RNAi) animals (not shown), 
demonstrating atic-1 encodes ATIC enzyme. The accumulation of SZMP and ZMP in 
adsl-1(RNAi) and atic-1(∆) was rather modest, by contrast we observed a robust 
accumulation of SAMP in adsl-1(RNAi). These results suggest that C. elegans purine 
biosynthesis relies mostly on the recycling pathway, at least in standard culture conditions. 
Noteworthy, ATP levels are slightly lower in adsl-1(RNAi) compared to wild-type (Figure 
1C), otherwise the abundance of ATP and GTP were not severely affected in the 
deficiencies analyzed.
As to the conservation of GPPAT, the HPLC analysis provided crucial functional 
evidence: neither SZMP was detected in ppat-1(∆); adsl-1(RNAi) (Figure 1C) nor was ZMP 
detected in ppat-1(∆); atic-1(∆) (Figure 1D), or ppat-1(∆); atic-1(RNAi) (not shown). This 
demonstrates that ppat-1 gene is indeed required for purine synthesis through the de novo 
pathway. Noteworthy, SAMP accumulation in ppat-1(∆); adsl-1(RNAi) is similar to 
adsl-1(RNAi) alone, providing an internal control for RNAi efficiency and further confirming 
SZMP accumulation in adsl-1(RNAi) is dependent on ppat-1. In summary, our metabolic 
profiling validates functional conservation of ADSL and ATIC, and demonstrates ppat-1 is 
required for the de novo pathway, consistent with the prediction that it encodes the GPPAT 
enzyme in C. elegans.
- Functional analysis of adsl-1
Because SZMP and SAMP are known to function as regulatory metabolites in other 
organisms (Rebora et al. 2001; Pinson et al. 2009; Keller et al. 2014; Gooding et al. 2015) 
and because they may play an important role in the etiology of the ADSL deficiency, we 
focused our functional analysis on adsl-1. In order to distinguish the effects of SZMP 
buildup from those due to the loss of de novo purine synthesis, we further include ppat-1 in 
our analysis. Moreover, in order to distinguish the effect of ADSL activity strictly in the de 
novo pathway, converting SZMP to ZMP, from the activity in converting SAMP to AMP, we 
used for comparison ATIC deficient worms. ATIC participates only in the de novo pathway 
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accumulating ZMP, which shares some targets with SZMP, at least in yeast (Rebora et al. 
2001; Pinson et al. 2009). Finally, in order to test whether phenotypes observed in 
adsl-1(∆) were due to SZMP buildup, we performed systematically epistasis analysis in the 
ppat-1(∆); adsl-1(∆) double mutant. Similarly, to test whether phenotypes in the atic-1(∆) 
mutant were caused by ZMP accumulation we performed epistasis in the ppat-1(∆); 
atic-1(∆) double mutant. Throughout the manuscript, we refer collectively as “purine 
mutants” to all three single mutant animals, plus the ppat-1(∆); adsl-1(∆) and ppat-1(∆); 
atic-1(∆) double mutants; and as “de novo” pathway mutants to ppat-1(∆), atic-1(∆) single 
mutants and ppat-1(∆); atic-1(∆) double mutant animals.
- adsl-1 is required for the maintenance of germline stem cells’ (GSCs).
The adsl-1(∆) homozygous animals display striking morphological defects, they are 
noticeably smaller than wild-type, sterile and often present a protruding vulva (Figure 2A). 
We observe a complete absence of oocytes and sperm cells in adsl-1(∆) and ppat-1(∆); 
adsl-1(∆) worms, only a reduced number of nuclei morphologically resembling the GSCs 
are detectable near the vulva, where the germline distal tip cell is found in wild-type 
animals (Figure S3A). By contrast, the de novo pathway mutants are viable and fertile, and 
the overall morphology is similar to wild-type worms. To better characterize the GSCs 
phenotype, we used a germline specific reporter transgene expressing H2B::GFP fusion in 
the GSCs, under the control of the pie-1 promoter (Praitis et al. 2001). While in ppat-1(∆) 
single mutants the germline is indistinguishable from wild-type, in adsl-1(∆) and ppat-1(∆); 
adsl-1(∆) animals sterility is fully penetrant and the germline is barely detectable if at all 
(Figure 2B). Indeed we observed 52.2% of adsl-1(∆) (n = 23) and 52% of ppat-1(∆); 
adsl-1(∆) animals (n = 25) had no detectable H2B::GFP, 43.5% of adsl-1(∆) and 44% of 
ppat-1(∆); adsl-1(∆) had 10 or less H2B::GFP positive nuclei, and 4.3% of adsl-1(∆) and 
4% of ppat-1(∆); adsl-1(∆) had barely above 10 H2B::GFP positive nuclei. Hence, adsl-1 is 
required for proliferation and/or maintenance of GSCs independently of ppat-1.
It has been shown that the sterility associated with a deficiency in the pyrimidine 
recycling pathway could be rescued by supplementation of the culture medium with 
pyrimidine nucleosides (Chi et al. 2016). We, thus tested whether supplementation with 
purine nucleosides could rescue adsl-1(∆) sterility. When cultured with 20 mM Adenosine 
(Ado in Figure 1A) in the medium from hatching until adulthood, both adsl-1(∆) (n = 55) 
and ppat-1(∆); adsl-1(∆) (n = 54) were sterile, much like the non-supplemented controls (n 
= 80 and n = 88, respectively). As expected, 100 mM Inosine (Ino in Figure 1A) 
supplementation had no effect in adsl-1(∆) (n = 28) nor in ppat-1; adsl-1(∆) (n = 64) 
sterility. Under the same conditions wild-type (20 mM Adenosine n = 86; 100 mM Inosine n 
= 99) and ppat-1(∆) (20 mM Adenosine n = 76; 100 mM Inosine n = 100) worms were 
fertile, to the same extent as non-treated controls (wild-type n = 116; ppat-1(∆) n = 114). 
We further tested whether Adenosine supplementation could rescue adsl-1 partial loss of 
function. When we performed adsl-1(RNAi) with 20mM Adenosine in the culture medium 
we observed 30.8% sterility (n=182) compared to 17.0% in absence of Adenosine 
supplementation (n=141), while mock RNAi produced 0% sterility, in both 20mM 
Adenosine or no Adenosine supplementation (n=101 and n=103 respectively). In 
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summary, we found no evidence that purine supplementation in the culture medium allows 
to recover the GSCs defects of adsl-1(∆).
As mentioned above, the de novo pathway mutants present a germline 
undistinguishable from wild-type, in contrast with the complete sterility of adsl-1(∆). In C. 
elegans, adult hermaphrodites reproduce through self-fertilization, with the number of 
progeny being modulated by food source and metabolic status (Houthoofd et al. 2002; 
Watson et al. 2014). In order to investigate whether the de novo pathway could impact the 
level of fertility, we measured total number of eggs laid by ppat-1(∆), atic-1(∆) and 
ppat-1(∆); atic-1(∆) hermaphrodites throughout their reproductive life. We observed that 
ppat-1(∆) fertility is in the wild-type range, while atic-1(∆) fertility is significantly lower 
(Figure S3B). Importantly, ppat-1(∆) is epistatic to atic-1(∆) regarding fertility, suggesting 
that ZMP accumulation, rather than de novo pathway impairment, might reduce fertility. To 
test this hypothesis, we cultured ppat-1(∆); atic-1(∆) in the presence of ZMP precursor 
AICAR (0.1 mM), under this condition internal ZMP builds up (see below). Consistent with 
our hypothesis, we observed reduced fertility in ppat-1(∆); atic-1(∆) treated with AICAR 
compared to the control (Figure S3B). Furthermore, wild-type worms cultured with 0.5 mM 
AICAR also displayed reduced fertility. We conclude that ZMP buildup in atic-1(∆) causes 
reduced fertility, while the de novo pathway per se has no impact on this phenotype, as 
ppat-1(∆) is similar to wild-type. Taken together these data show that adsl-1 is essential for 
germline integrity, while de novo pathway genes ppat-1 and atic-1 are dispensable.
The strong germline defects in adsl-1(∆) prompted us to investigate whether adsl-1 
is required during early embryonic development. We therefore examined the viability of 
ADSL deficient embryos. adsl-1(∆) sterility precludes the analysis of homozygous embryos 
devoid of maternal contribution. We first analyzed zygotic requirement by examining the 
progeny of adsl-1(∆)/+ heterozygotes (see Materials and Methods); if adsl-1 zygotic 
expression were strictly essential in the embryo one would expect no adsl-1(∆) 
homozygous progeny, and a mendelian ~25% proportion of embryonic lethality, instead we 
observed only 7.7% of dead embryos. Therefore, either adsl-1 is not essential for embryo 
development or maternal contribution is, at least in part, sufficient. To further investigate 
adsl-1 function in the early embryo we used RNAi, which depletes maternally expressed 
mRNAs. Because adsl-1 full penetrant loss-of-function leads to sterility, we performed 
adsl-1(RNAi) knock-down, starting at the L4 stage - resulting in a partial loss-of-function. 
Under these conditions, we observed 32.2% embryonic lethality in adsl-1(RNAi) (Figure 
S3C), suggesting adsl-1 is required for embryonic development, and maternal expression 
contributes to adsl-1 function at this stage. To test whether the de novo pathway is 
necessary for embryo development we performed adsl-1(RNAi) in the ppat-1(∆), resulting 
in 31.5% embryonic lethality. The observation that ppat-1(∆) does not enhance 
adsl-1(RNAi) hypomorphic phenotype suggests the de novo pathway does not contribute 
to embryonic development (see bellow). Consistent with this hypothesis, the de novo 
pathway mutants, display an embryonic development indistinguishable from wild-type: 
nearly 100% of the laid eggs hatched in all the de novo pathway mutants as in WT 
controls. Thus adsl-1 function in the recycling pathway is required for proper embryonic 
development.
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- adsl-1(∆) leads to small body size phenotype.
The overall morphology observed in adsl-1(∆) and ppat-1(∆); adsl-1(∆) 
(morphologically indistinguishable from adsl-1(∆) single mutants) suggests that cell lineage 
specification and morphogenesis are not affected. No defects were observed in somatic 
tissues of adsl-1(∆) other than the vulva, including pharynx, intestine or hypodermis, and 
animals are viable and mobile. Hence the smaller size does not seem to result from 
defects in fate specification. To better characterize this phenotype, we measured body 
length in adult worms. adsl-1(∆) are significantly smaller than wild-type and similar to 
ppat-1(∆); adsl-1(∆), while the de novo mutants are indistinguishable from the wild-type 
(Figure 2C). Given the volume occupied by the germline in adult C. elegans we wondered 
whether sterility could account for the small size in adsl-1(∆), we therefore compared 
adsl-1(∆) to glp-1(e2141) mutants, known to lack a germline when cultured at 25°C (Priess 
et al. 1987). Given adult glp-1(e2141) length is in the wild-type range (Figure 2C), sterility 
cannot account for the small size of adsl-1(∆). Noteworthy, newly hatched adsl-1(∆) 
animals are the same size as wild-type and morphologically indistinguishable (not shown), 
hence size defects are likely to manifest during post-embryonic development. We 
conclude adsl-1 is requiredfor adult body size independently of the sterility phenotype. By 
contrast deficiencies in GPPAT or ATIC in the de novo pathway do not affect this trait.
- adsl-1 is required for normal developmental timing and lifespan.
The small size of adsl-1(∆) prompted us to investigate whether post-embryonic 
development was impaired. Given newly hatched adsl-1(∆) are indistinguishable from wild-
type, we hypothesized the growth defects were linked to abnormal larval development. 
Upon hatching, and before adulthood, C. elegans goes through four larval stages each 
followed by an inactive state known as lethargus during which a molt takes place 
(Cassada and Russell, 1975). Importantly, this sequence follows a highly reproducible 
timing under standard culture conditions (Byerly et al. 1976). We therefore measured 
timing of post-embryonic development in purine mutants, using the method described by 
Olmedo et al (Olmedo et al. 2015). Briefly, newly hatched L1 larvae carrying a transgenic 
luciferase are cultured in presence the of luciferin, emitting luminescence when active 
(Lagido et al. 2008). Since larvae cease feeding during lethargus, they stop taking the 
substrate and a drastic drop in luminescence is observed. Therefore, monitoring the 
luminescence of individual larvae allows to precisely time the occurrence of each larval 
(high luminescence) and lethargus (low luminescence) phases (Figure S4A; Olmedo et al. 
2015). We observed that both adsl-1(∆) and ppat-1(∆); adsl-1(∆) present a strongly 
delayed post-embryonic development (Figure 3A, Supplemental Figure 4B). Although all 
larval and lethargus phases are affected in adsl-1(∆) mutants, the delay is more 
pronounced as post-embryonic development progresses. By contrast, the overall timing of 
post-embryonic development is not affected in de novo pathway mutants. We therefore 
conclude that adsl-1 is required for normal post-embryonic developmental timing, whereas 
de novo pathway genes ppat-1 and atic-1 are not.
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Post-embryonic development, metabolism and the germline are all known to impact 
lifespan in C. elegans (reviewed in Antebi, 2013). Because of adsl-1(∆) sterility and 
developmental delay we measured the lifespan of the purine mutants. adsl-1(∆) mutant 
has a shorter lifespan that wild-type (Figure 3B). By contrast, the de novo pathway 
mutants’ lifespan is indistinguishable from wild-type (Figure 3B). Importantly, ppat-1(∆) 
suppresses the adsl-1(∆) short-lifespan phenotype as ppat-1(∆); adsl-1(∆) double mutant 
survival profile is in the wild-type range (Figure 3B). These results strongly suggest that 
SZMP buildup in adsl-1(∆), rather than ADSL activity per se is responsible for the reduced 
lifespan. Moreover, we conclude that the developmental delay and sterility of adsl-1(∆) are 
not linked to lifespan.
- Ascribing adsl-1(∆) phenotypes to the de novo vs recycling pathway
Most of defects we observed in adsl-1(∆) - germline, vulva, adult size, embryonic 
and post-embryonic development - are not observed in ppat-1(∆) or atic-1(∆) mutants, 
suggesting ADSL activity of converting SAMP in AMP is the cause of these phenotypes. 
However, the question of the relative contributions of the de novo and recycling pathways 
remains open as SAMP to AMP conversion by ADSL has the peculiarity of being required 
for the synthesis of AMP both through the de novo and recycling pathways (as is IMP to 
SAMP conversion by ADSS, Figure 1). Thus, two hypotheses can explain the adsl-1(∆) 
defects regarding SAMP to AMP conversion: either these defects are linked to the 
recycling but not the de novo pathway, or both the recycling and the de novo pathways 
contribute redundantly to the phenotypes, such that in ppat-1(∆) mutants the recycling 
pathway can compensate for the absence of the de novo pathway. Given ADSL functions 
both in the de novo and recycling pathways, the putative null adsl-1(∆) does not allow to 
discriminate between de novo and recycling pathway contributions. However, the analysis 
of adsl-1 or adss-1 partial loss-of-function does. In such condition, if the first hypothesis 
were true abolishing the de novo pathway would have no impact on adsl-1 or adss-1 
partial loss-of-function phenotypes, while as if the second hypothesis were true the 
penetrance of the phenotypes should increase when adsl-1 or adss-1 partial loss-of-
function is combined with ppat-1(∆).
We performed adsl-1(RNAi) and adss-1(RNAi) treatment - producing a partial loss-
of-function - in wild-type and ppat-1(∆) worms, and analyzed the germline and vulval 
defects. We observe no increase in penetrance of either phenotype when comparing wild-
type and ppat-1(∆), both upon adsl-1(RNAi) and adss-1(RNAi) (Table 1). Similarly, as 
described above, adsl-1(RNAi) displays the same penetrance of embryonic lethality in 
wild-type and ppat-1(∆) backgrounds (Figure S3C). We conclude that adsl-1(-) defects, at 
least in the germline, vulva and embryonic development, are linked to the purine recycling 
pathway, while the de novo pathway has no detectable contribution.
- adsl-1(WT) transgene rescues adsl-1(∆) phenotypes
Given adsl-1(∆) allele was generated by random mutagenesis, it is possible the 
phenotypes observed are caused by other mutations in the genetic background. In order to 
verify whether adsl-1 loss-of-function was indeed the cause for the observed phenotypes, 
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we performed a transgene rescue assay. We generated a plasmid containing adsl-1(WT) 
allele genomic fragment including ~1Kb upstream the start codon and ~1Kb downstream 
the stop codon (see material and methods) and transformed adsl-1(∆)/+ animals through 
microinjection the. We obtained transgenic animals, carrying the adsl-1(∆) allele (either 
heterozygous or homozygous) and the adsl-1(WT) transgene. In seven independent 
transgenic clones we were able to observe rescue of adsl-1 function in adsl-1(∆) 
homozygous animals. Rescued adsl-1(∆) homozygous laid broods bearing viable 
embryos, hence transgenic adsl-1(WT) rescued the germline phenotype. Furthermore 
rescued adsl-1(∆) homozygous presented an overall wild-type like adult morphology, 
including WT-like vulva. Therefore transgenic adsl-1(WT) rescued body size and vulval 
defects as well. Given the extra-chromosomal arrays carrying the adsl-1(WT) transgene 
were poorly transmitted to the progeny, we could not characterize these lines further. We 
conclude that adsl-1(∆) phenotypes - at least sterility, vulval defects and body size - are 
caused by adsl-1 loss-of-function. Further supporting this conclusion adsl-1(RNAi) leads to 
sterility and vulval defects (see above, Table 1), matching what would be expected for a 
partial loss-of-function compared to adsl-1(∆), and adss-1(RNAi), depleting ADSS - the 
enzyme immediately upstream of ADSL in the recycling pathway - phenocopies 
adsl-1(RNAi) as would be expected.
- Imbalance in purine metabolism impacts locomotion
Given the severe muscular and neuronal symptoms of ADSL deficiency patients 
(Jaeken et al. 1988; Spiegel et al. 2006; Jurecka et al. 2015), we sought to investigate 
muscle and neural defects in adsl-1(∆) worms. In order to address muscle function, we 
performed a locomotion assay (Figure 4A; Zheng et al. 1999; Hart, 2006), and observed 
that adsl-1(∆) mutants were slower than WT (Figure 4B). atic-1(∆) mutants, were also 
slower than wild-type, albeit to a lesser extent (Figure 4B), suggesting the de novo 
pathway could have a role in locomotion. However, ppat-1(∆) animals were 
indistinguishable from wild-type, thus de novo pathway per se does not affect locomotion. 
Moreover, the locomotion defect in adsl-1(∆) was not suppressed by ppat-1(∆), ppat-1(∆); 
adsl-1(∆) was actually slower than adsl-1(∆) single mutant. Thus, ADSL activity, 
independently of SZMP buildup, accounts for the adsl-1(∆) locomotion defect. By contrast, 
atic-1(∆) locomotion defect was suppressed by ppat-1(∆) as ppat-1(∆); atic-1(∆) speed was 
in the wild-type range. Hence, slower locomotion in atic-1(∆) is linked to ZMP build up, 
rather than the de novo pathway per se.
- AICAR treatment
The ADSL product ZMP is known to activate AMPK by mimicking AMP (Jin et al. 
2007), and AICAR treatment is known to impact muscle function in mice, presumably 
through ZMP induced AMPK activation (Narkar et al. 2008). To test whether ZMP is 
responsible for the locomotion defects in atic-1(∆), we tested whether providing the worms 
with external AICAR would impact locomotion. We treated late L4 stage wild-type and de 
novo pathway mutants with AICAR, for 24 hours. Somewhat surprisingly AICAR treatment 
did not significantly affect locomotion in any genotype tested (Figure S5A). Given this 
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surprising result, we performed metabolic profile analysis of AICAR treated worms. As 
expected, we observed higher levels of AICAR upon treatment, and noticeably a significant 
buildup of both ZMP and ZTP in all treated genotypes (Figure S5B), showing AICAR was 
efficiently internalized and phosphorylated. As expected ZMP levels are higher in atic-1(∆) 
than in other genotypes due to cumulative buildup of ZMP from the de novo pathway and 
from AICAR treatment (Supplementay Figure 5C). Therefore, buildup of ZMP in adult 
worms per se does not explain the reduced locomotion observed in atic-1(∆). Importantly, 
while AICAR treatment did not significantly affect ATP levels across genotypes, it led to an 
increase in uric acid, particularly in atic-1(∆) and ppat-1(∆); atic-1(∆). Moreover, we also 
observed, in all treated genotypes, an accumulation of ADSL substrate SZMP and its 
riboside form SAICAR. Therefore, AICAR treatment leads to increased levels of ZMP as 
expected, but also of uric acid, ZTP and SZMP (Figure S5B). The SAICAR and SZMP 
accumulation indicates that not only SZMP to ZMP conversion by ADSL is inhibited by 
AICAR treatment, this reaction can even be reversed, given SZMP was detected in 
ppat-1(∆) and ppat-1(∆); atic-1(∆) mutants (Figure S5B, see Figure S1B). Accordingly, in 
yeast, ADSL enzyme has been shown to convert ZMP in SZMP when ZMP is in excess 
(Rebora et al. 2005), which seems to also be the case for C. elegans ADSL.
- Muscle structure, but not the neuromuscular junction, is disrupted in adsl-1(∆)
One possible explanation for the locomotion defects observed in atic-1(∆) and 
adsl-1(∆) is that the neuromuscular junction is compromised. We therefore tested whether 
purine mutants were sensitive to Levamisole and Aldicarb. Both drugs activate 
acetylcholine receptors at the neuromuscular junction in C. elegans, at either the pre-
synapse (Aldicarb) or post-synapse (Levamisole) leading to paralysis of wild-type worms 
(Lewis et al. 1980), while mutants with defective cholinergic neuromuscular junction are 
not affected (Fleming et al. 1997; Gendrel et al. 2009). We found no significant differences 
among purine mutants and wild-type animals (Figure S6A and B), demonstrating that the 
neuromuscular junction remains functional upon purine metabolism deficiencies. We 
therefore tested whether other neuronal functions might be impaired in purine mutants. We 
performed a standard touch assay (Hobert et al. 1999; Hart, 2006). We observed a similar 
response to touch in all purine mutants as in the wild-type, thus in our experiments the 
mechanosensory function as well as the behavioral response are intact in purine mutants 
(Figure S6C). In summary, we found no evidence for neuronal dysfunction in the purine 
metabolism mutants tested.
Given these results, we hypothesized that the locomotion defects we observed 
could be explained by muscle malfunction. We performed an analysis of muscle cell 
structure through immunohistochemistry and confocal microscopy. As expected, we 
observed regular parallel arrangement of myosin fibers in the wild-type (Figure 5A), while 
in adsl-1(∆) mutants (n = 13), muscle myosin fibers formed an irregular meshwork and 
muscle mass seemed reduced (Figure 5B). In atic-1(∆) (n = 14), by contrast, the structure 
of muscle myosin fibers was indistinguishable from wild-type controls (Figure 5C, n = 10), 
as are ppat-1(∆) (Figure 5D, n = 13). Furthermore ppat-1(∆); adsl-1(∆) (Figure 5E, n = 10) 
displayed the same muscle fiber defects as adsl-1(∆), while ppat-1(∆); atic-1(∆) were 
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indistinguishable from ppat-1(∆) and atic-1(∆) single mutants (Figure 5F, n = 15), showing 
that de novo pathway deficiency does not affect muscle structure (Figure 5). These results 
show ADSL is required for muscle integrity, while deficiencies in the de novo pathway have 
no discernible effect on this trait. Muscle structure defects could account for the locomotion 
defects of adsl-1(∆).
Discussion
- A nematode model to study ADSL deficiency and, more broadly, purine metabolism
We describe here the phenotypes and metabolic profiles associated with three 
deficiencies in the purine biosynthesis pathway in the nematode C. elegans, focusing on 
ADSL deficiency. This study provides a reference to future investigation of the underlying 
molecular mechanisms. The phenotypes observed are to some extent genetically 
separable. Particularly the most severe defects in the adsl-1(∆) mutant - muscle, germline 
and development - are not shared with ppat-1(∆) and atic-1(∆) mutants. The model we put 
forward links these defects to the ADSL activity in converting SAMP in AMP as the critical 
enzymatic step in ADSL deficiency (Figure 6). For instance, there is a long-standing 
debate concerning the etiology of the pathology associated with ADSL deficiency. It has 
been proposed that the SAICAR/S-Ado ratio correlated with specific symptoms (Jaeken et 
al. 1988; Race et al. 2000), while more recent studies found no evidence for such 
correlation (Jurecka et al. 2008; Zikanova et al. 2010). Studies in human subjects are of 
limited reach, while a genetically amenable model organism shall allow to investigate 
mechanisms underlying specific phenotypes. In our model, SAMP to AMP conversion is 
crucial, hence SAMP buildup could play a significant role in the ADSL deficiency. 
Notwithstanding the evolutionary distance between nematodes and humans, testing this 
hypothesis may be informative to the human pathology. However, at this point, caution is 
advised when comparing our results to the human pathology, more research is required to 
address this issue. Importantly, the reported mutations causing ADSL deficiency in humans 
are associated with a residual enzymatic activity (reviewed in Nyhan, 2005; Kelley and 
Andersson, 2014), contrasting with our analysis of putative null mutants. The use of null 
mutations allows to carefully establish the phenotypes associated with ADSL deficiency in 
the nematode model, and shall allow to further establish tissue specific contributions and 
perform epistasis analysis in order to ascribe phenotypes to different steps in the pathway. 
Only once this characterization is achieved, mutations comparable to human ADSL 
deficiency, can be modeled with C. elegans and provide further insight. In summary, 
although further investigation is required, C. elegans as metazoan model organism 
provides the means to investigate the metabolic regulation of developmental progression, 
muscle defects or cell proliferation in the context of ADSL deficiency, as well as in other 
deficiencies in the purine biosynthesis pathway.
- Purine recycling and GSCs maintenance
One striking phenotype of adsl-1(∆) is the severe reduction in GSCs, leading to 
sterility. In adult C. elegans, the germline is the sole proliferating tissue. More precisely, 
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GSCs in the distal gonad proliferate under the control of Notch signaling from neighboring 
somatic cells, while in the proximal region the germline nuclei enter meiotic differentiation 
(reviewed in Kimble and Crittenden, 2005; Hansen and Schedl, 2013). Interestingly, 
deficiencies in both the pyrimidine (Chi et al. 2016) and pyridine nucleotides (a.k.a. NAD+) 
recycling pathways (Vrablik et al. 2009) have also been linked to germline defects in C. 
elegans, suggesting nucleotide metabolism to play a critical role in maintaining the GSCs 
pool. Importantly however, adsl-1(∆) phenotype is more severe than in either case. In 
pnc-1(-) mutants, affecting the pyridines salvage pathway, animals are fertile despite 
germline defects. In cdd-1/2(-) mutants, deficient for the Cytidine Deaminase in the 
pyrimidine recycling pathway, GSCs proliferation could be restored with pyrimidine 
supplementation. By contrast, purine supplementation had no effect on either adsl-1(∆) or 
adsl-1(RNAi) - partial loss-of-function - suggesting the shortage in the final products of the 
purine pathway is not the main factor causing GSCs defect. While one cannot exclude the 
defects in pnc-1(-), cdd-1/2(-) and adsl-1(∆) are unrelated, the three metabolic pathways 
are closely connected. It is therefore plausible that germline defects in these three mutants 
share a common mechanism, through crosstalk among these metabolic pathways. In that 
case, the severity of the adsl-1(∆) phenotype remains to be explained. One tempting 
explanation is that the primary metabolic defect lies on the purine pathway, and that 
imbalance in the other nucleotide biosynthesis pathways impact purine metabolism as an 
indirect consequence. It is known that GSCs proliferation is influenced by environmental 
factors, particularly nutrient availability, and is likely regulated by metabolic signals 
(reviewed in Hubbard et al. 2013). Our results are consistent with the purine recycling 
pathway serving as sensor integrating nucleotide pathways’ status, and providing a 
metabolic signal regulating GSCs proliferation.
Interestingly, the purine biosynthesis pathway has been shown to play a role in the 
balance between proliferation and differentiation in both stem cells and cancer cells, with 
inhibition of purine synthesis leading to increased differentiation at the expense of 
proliferation (Oburoglu et al. 2014; Tardito et al. 2015). A similar mechanism could explain 
adsl-1(∆) GSCs defect, in that scenario the ADSL deficiency would lead to germline nuclei 
entering meiosis at the expense of proliferation.
- Purine metabolism and development
Metazoans often control their development in response to environmental conditions, 
namely nutrient availability. This control involves metabolic regulation, for instance through 
Insulin/Insulin-like or mTOR pathways (reviewed in Danielsen et al. 2013). In C. elegans 
the adult worm size varies depending on the bacterial food source (Samuel et al. 2016), 
suggesting size is one of the developmental phenotypes subjected to metabolic regulation. 
This regulation could, in theory be due to metabolic regulation of cell fate decisions, or 
alternatively be a consequence of metabolic regulation of cell size. In adsl-1(∆), based on 
our analysis, only GSCs and vulval cells present cell fate abnormalities in the adult, which 
have no impact in overall adult size. Hence the small size we observe is most likely due to 
an effect of purine metabolism on cell size. In addition to size, adsl-1(∆) also displays a 
strong delay during post-embryonic development. In C. elegans progression through larval 
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stage and molting cycles is highly regulated, involving oscillations of LIN-42, the 
orthologue the circadian protein PERIOD (Monsalve et al. 2011; Edelman et al. 2016; 
reviewed in Monsalve and Frand, 2012). The developmental changes associated with this 
progression involve a tight coordination of different cell lineages across the worm’s body, 
and are very well characterized, as are the genetic pathways involved (reviewed in 
Rougvie and Moss, 2013). By contrast, the upstream mechanisms and signals triggering 
or modulating these developmental transitions are poorly understood. The quality and 
amount of food available certainly play a role, as they have been shown to impact the 
timing of post-embryonic development (Houthoofd et al. 2002; MacNeil et al. 2013). The 
dramatic developmental delay in adsl-1(∆) points at a metabolic regulation of these 
developmental transitions involving the purine recycling pathway.
Our results also suggest a role for ADSL in embryonic development. Presumably, a 
more penetrant adsl-1 loss-of-function would lead to higher levels of embryonic lethality, 
however the ensuing sterility precludes further study of early development. With the tools 
currently available we cannot determine conclusively the extent of adsl-1 requirement in 
embryonic development. Given most homozygous adsl-1(∆) embryos - where only zygotic 
adsl-1 expression is affected - are viable, and RNAi - depleting maternal mRNA - leads to 
embryonic lethality it is plausible that proper embryo development requires adsl-1 function, 
ensured, at least in part, by maternal contribution.
One possibility to explain the developmental phenotypes in adsl-1(∆) could be 
limiting ATP, causing namely slow development and smaller size. We have observed that 
in adsl-1(∆) food uptake is reduced compared to wild-type (Rodríguez-Palero et al. 2018), 
thus not only ATP but limiting overall bulk nutrients could account for the developmental 
defects observed. Although limiting nutrients and ATP levels are important factors, and 
certainly have a sizable impact, other elements suggest this hypothesis does not suffice to 
explain the adsl-1(∆) defects. In eat mutants, known to have feeding impairment, food 
uptake defects don’t always correlate with developmental delay (M.O. and M.A.S. 
unpublished results). As to ATP levels, our metabolic profiles show them to be only slightly 
reduced in adsl-1(RNAi), compared to wild-type. This is not so surprising given adenine or 
adenosine are available from the bacterial food source could be used to produce ATP 
despite ADSL deficiency (see Figure 1A). An alternative hypothesis is that post-embryonic 
developmental and adult size are regulated by the wiring of the purine recycling pathway, 
rather than the synthesis of its final products. In this view, purine intermediate metabolites 
could function as metabolic sensors modulating developmental progression.
- Purine metabolism and neuro-muscular function
Both neuronal and muscle tissues are severely affected in purine metabolism 
syndromes, suggesting these two tissues are particularly susceptible upon purine 
metabolism impairment in patients. In our nematode model, we observed locomotion 
defects associated with both ATIC and ADSL deficiencies. Somewhat surprisingly, no 
discernible neuronal dysfunction was observed in any purine mutant. All of the genotypes 
tested displayed sensitivity to Levamisole and Aldicard, similarly to wild-type controls, 
showing neuromuscular junction was still functional. Moreover, mechanosensory response 
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in purine mutants was not affected either. Hence, we could not identify neuronal 
dysfunctions to account for the locomotion defects. Notwithstanding, given we did not 
investigate directly neuron integrity, it remains possible that purine mutants present 
neuronal impairments that the functional assays reported here do not allow to detect.
We did however find evidence for muscle abnormalities that could explain the 
locomotion defects. Noteworthy, the locomotion defects we observed in atic-1(∆) and 
adsl-1(∆) were linked to different mechanisms. Contrary to adsl-1(∆), the locomotion delay 
in atic-1(∆) was suppressed in the ppat-1(∆); atic-1(∆) double mutant, hence linked to ZMP 
buildup. One possible explanation is that ZMP accumulation leads to metabolic changes 
that in turn impact muscle function, possibly through AMPK activation (Jin et al. 2007). 
Importantly, the structure of muscle myosin fibers in atic-1(∆) are undistinguishable from 
the wild-type, thus muscle integrity seems not to be affected in atic-1(∆). The ZMP effect 
on locomotion, however, is not straightforward; upon AICAR treatment of L4 larvae / young 
adults ZMP builds up as expected, nonetheless locomotion is not affected. Although the 
mechanism remains elusive, our results suggest that either ZMP effect on locomotion is 
developmental and occurs prior to the L4 stage, or ZMP accumulation from external 
AICAR does not affect the same tissues as endogenous ZMP build up in atic-1(∆).
On a side note, because ZMP is an AMPK agonist (Jin et al. 2007), its riboside form 
AICAR is often added to culture media in different model organisms, including C. elegans 
(Moreno-Arriola et al. 2016; Ahmad and Ebert, 2017), to trigger AMPK activation upon 
intracellular conversion to ZMP. Our results show that increase of ZMP is not the only 
metabolic consequence of AICAR treatment, therefore caution is recommended when 
attributing phenotypes to AMPK activation.
As to the locomotion defects in adsl-1(∆), our results point to ADSL activity in the 
purine recycling pathway, given ppat-1(∆) does not suppress the locomotion phenotype, 
quite to the contrary. Furthermore, adsl-1(∆) is associated with significant damage in the 
structure of muscle myosin fibers, suggesting that locomotion defects are caused by 
muscle defects. While the underlying cause for these defects is yet to be determined, we 
hypothesize that the developmental delay in adsl-1(∆) may contribute to muscle defects.
- Purine metabolic network in a metazoan model
The results we present show the functional conservation of both the de novo and 
recycling purine biosynthesis pathways in C. elegans. Furthermore, we characterized 
phenotypes associated with the deficiencies in the critical enzymes ADSL and ATIC. While 
several phenotypes are genetically separable (Figure 6), it stands out that the most severe 
phenotypes - lack of GSCs, developmental delay and muscle integrity - are associated 
with ADSL activity, whilst deficiencies in the de novo pathway are viable and lead to rather 
subtle phenotypes - as reduced fertility and slower locomotion. Noticeably, the deletion of 
ppat-1 - which we show is required for the de novo pathway - produces no detectable 
phenotype in our culture conditions. The phenotypes observed in atic-1(∆), locomotion 
defects and reduced fertility, are associated with ZMP accumulation, rather than to 
shortage in purine synthesis through the de novo pathway, as though the de novo pathway 
per se is dispensable. It might seem paradoxical that the purine de novo pathway is 
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conserved while having no essential function. Indeed, a number of biosynthesis pathways, 
namely amino-acids, have been lost during metazoan evolution (Payne and Loomis, 2006) 
likely because amino-acids are available from the food source, as are nucleotides. 
However, our culture conditions may not reflect the natural environment in which C. 
elegans evolved; it is plausible that the de novo pathway is essential in different 
environments where purines are scarce.
Contrasting with our results in C. elegans, Drosophila mutants in a GPPAT encoding 
genes are lethal prior to adulthood (Malmanche and Clark, 2004; Ji and Clark, 2006). 
These Drosophila mutants are purine auxotroph - lethality is higher in purine deprived food 
source - and lethality is observed during the pupal phase, a closed developmental stage 
were external nutrients are not available. These different consequences of GPPAT 
deficiency in C. elegans and Drosophila could owe to substantially different metabolic 
requirements in the two species for GPPAT, and the whole de novo pathway; they could 
also reflect different life cycles and different experimental conditions. Further highlighting 
the contrast between Drosophila and C. elegans, fly mutants deficient for ADSL and ADSS 
are also lethal, in this case at larval stages prior to pupation (Stenesen et al. 2013). 
Interestingly, the authors show that ADSS and ADSL lower levels in heterozygous lead to 
increased lifespan through reduced AMP synthesis. Noteworthy, purine pathway mutants 
in yeast S. cerevisiae have been reported to increase chronological age (Matecic et al. 
2010). In both cases purine supplementation of the culture media restores wild-type 
phenotype, presumably through raising AMP levels to a wild-type range. If the same 
scenario occurs in C. elegans, our results on the lifespan of purine mutants could be 
explained by the abundance of purines in the bacterial food source. This possibility 
emphasizes the contribution purine availability in the external medium to the phenotypic 
outcomes. Further investigation of the purine pathway in worms will certainly involve 
controlled manipulation of purine supplementation, which requires a suitable defined 
culture medium (Flavel et al. 2018).
Actually, if one draws a parallel with yeast, it’s the severity of the adsl-1(∆) 
phenotypes that seems surprising, considering Ade13 null mutants in S. cerevisiae are 
viable when cultured with adenine (Dorfman, 1969). Given purines are available from the 
food source, one would have expected the worm to synthesize AMP and GMP despite 
ADSL deficiency. Indeed, external adenine and adenosine can be converted in AMP by 
Adenine phosphoribosyltransferase and Adenosine kinase respectively, both of which have 
orthologues in C. elegans (Figure S1A), and AMP can be converted in GMP (Figure 1A). 
The severity of adsl-1(∆) phenotypes, suggests that ADSL became essential even when 
external purines are available. Importantly, in humans, purines are also available from the 
food source, and all diseases affecting purine metabolism, but one, are linked to enzymes 
in the recycling pathway; with the notable exception being AICA-ribosiduria - deficiency in 
ATIC, in which ZMP buildup may be a crucial disease factor (Marie et al. 2004; Nyhan 
2005; Kelley and Andersson 2014). The emerging picture is that in metazoans the less 
energetically costly recycling pathway evolved to become the predominant form of purine 
metabolism, at least in favorable environmental conditions. Hence, specific functions 
evolved to strongly rely on the recycling pathway, independently of the abundance of 
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external purine sources. The defects associated with ADSL deficiency, as other recycling 
pathway deficiencies, could be the consequence of insufficient synthesis of the final 
products AMP and GMP as much as unbalanced wiring of the pathway, namely 
deregulation caused by intermediate metabolites.
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Figure 1 - Purine metabolism in C. elegans. (A) Schematics of the Purine Biosynthesis 
pathways in C. elegans based on sequence homology. Enzymes subjected to functional 
analysis are represented in red, other enzymes in green and metabolites in black. (B) Drop 
test to assess adenine auxotrophy in yeast S. cerevisiae mutants deficient for enzymes 
ADSL (ade13∆), ATIC (ade16∆ ade17∆) or GPPAT (ade4∆) expressing respectively C. 
elegans genes adsl-1, atic-1b and ppat-1. Expression of S. cerevisiae genes ADE13, 
ADE17 and ADE4 was used as positive control, and expression vector without insert as 
negative control. A culture with adenine is shown as auxotrophy control. In all drop tests 
presented, four drops are shown per condition, corresponding to serial dilutions (1:10) of 
cellular suspensions, with deceasing cell concentrations from left to right. (C) Zoom in on 
HPLC chromatogram peaks of specific metabolites SAICAR (SZMP riboside form), SZMP, 
sAdo (succinyl-Adenosine, SAMP riboside form), SAMP, ATP and GTP, upon adsl-1(RNAi) 
and ppat-1(∆); adsl-1(RNAi). (D) Zoom in on HPLC chromatogram peaks of specific 
metabolites SAICAR (SZMP riboside form), SZMP, AICAR (ZMP riboside form), ZMP, ATP 
and GTP, in atic-1(∆) and ppat-1(∆); atic-1(∆). Abreviations: Ade - adenine, Ado - 
adenonsine, SAdo - succinyl-adenosine, Ino - Inosine, Hypox - hypoxantine, Xant - 
Xantine, Gua - guanine, Guo - guanosine. In panels (C) and (D), scales are adjusted 
differently among metabolites, in order to highlight differences between genotypes.
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Figure 2 - Developmental defects in purine mutants. (A) DIC whole body images of 
representative young adults for each of the genotypes studied (bar= 200 µm). (B) 
Fluorescence micrographs of worms expressing H2B::GFP in the germline under the 
control of the pie-1 promoter. Arrows point at rare germ nuclei expressing H2B::GFP; 
spotty pattern throughout adsl-1(∆) and ppat-1(∆); adsl-1(∆) corresponds to intestinal auto-
fluorescence (bar= 25 µm). (C) Tukey box plot depicting body length of all purine mutants 
and glp-1(-) for comparison (means statistically different - one-way ANOVA - indicated 
pValues refer to comparison with wild-type - Bonferroni multiple comparison t-Test - 
otherwise comparison to wild-type bears no significant difference; n= 30 for all genotypes).
Figure 3
Figure 3 - Life traits in purine mutants. (A) - Graph depicting duration of post-embryonic 
developmental stages, white bars represent larval stages, from L1 to L4 (left to right), 
orange bars represent lethargus phases consecutive to each larval stage (mean durations 
of larval develepment, from t0 until exit from fourth lethargus phase, are statistically 
different - one-way ANOVA - indicated pValues refer to comparison with wild-type - 
Bonferroni multiple comparison t-Test - otherwise comparison to wild-type bears no 
significant difference; see detailed representation of the data in Figure S4). (B) Graph 
depicting fraction of alive worms over time for all genotypes studied (pValue indicated for 
the adsl-1(∆) vs wild-type comparison, all other genotypes are not significantly different 
from wild-type are significantly different from adsl-1(∆) - log rank test with Bonferroni 
correction; total combined of three independent experiments for each genotype, wild-type 
n= 106, ppat-1(∆) n= 91, atic-1(∆) n= 126, ppat-1(∆); atic-1(∆) n= 149, adsl-1(∆) n= 227, 
ppat-1(∆); adsl-1(∆) n= 113). 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Figure 4 - Locomotion of purine mutants. (A) Cartoon schematics of the locomotion 
behaviour assay. (B) Graph depicting the average locomotion speed in all purine mutants 
(error bar - standard error of the mean; n = 30 in all genotypes except wild-type and 
ppat-1(∆); atic-1(∆) n= 40; means statistically different - one-way ANOVA - indicated 
pValues refer to comparison with wild-type - Bonferroni multiple comparison t-Test - wild-
type, ppat-1(∆) and ppat-1(∆) adsl-1(∆) are not statistically different from one another).
Figure 5
Figure 5 - Muscle structure in purine mutants. Confocal micrographs of muscle myosin 
immunostaining in young adult’s body wall muscle cells of all studied purine mutants (bar= 
10µm). (A) Wild-type. (B) adsl-1(∆). (C) atic-1(∆). (D) ppat-1(∆). (E) ppat-1(∆); adsl-1(∆). 
(D) ppat-1(∆); atic-1(∆).
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Figure 6 - Summary of the functional analysis of the purine biosynthesis pathway in C. 
elegans reported in this study. 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Table 1 - Germline and vulval phenotypes in adsl-1(RNAi) and adss-1(RNAi). All strains 
carry the germline specific pie-1p::H2B:GFP. Three classes of sterile phenotypes were 
defined based on the number of GFP positive germline nuclei. Vulval phenotypes were 
scored on DIC (Nomarski) microscopy.
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Table 1
Genotype
(+pie-1p::H2B::GFP)
Sterile
no germline
Sterile
<10 germ cells
 Sterile
>10 germ cells
 WT-like
germline
n=
(germline)
Protruding
vulva
WT-like
vulva
n=
(vulva)
WT 0% 0% 2,3% 97,7% 43 0% 100% 35
ppat-1(∆) 0% 0% 0% 100% 57 0% 100% 57
adsl-1(RNAi) 8,1% 0% 51,4% 40,5% 37 26,1% 73,9% 23
ppat-1(∆); adsl-1(RNAi) 3,4% 0% 27,6% 69,0% 29 0% 100% 28
adss-1(RNAi) 1,7% 1,7% 57,9% 38,8% 121 8,0% 92,0% 50
ppat-1(∆); adss-1(RNAi) 0% 0% 7,7% 92,3% 52 0% 100% 39
 1
Supplementary Figures
Figure S1
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% 
Similarity
% 
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1 GPPAT PPAT-1 PPAT 63 46 ADE4 51 32
2 GART/AIRS F38B6.4 (N-ter)
GART 62 44
ADE5,7 58 39
3 GARS F38B6.4 (C-ter) ADE8 51 30
4 FGARAT F10F2.2 PFAS 62 47 ADE6 52 34
5 AIRC PACS-1 (C-ter)
PAICS 69 51
ADE2 47 32
6 SAICARS PACS-1 (N-ter) ADE1 40 20
7 ADSL ADSL-1 ADSL 64 47 ADE13 61 43
8 ATIC ATIC-1 ATIC 75 60 ADE16/17 72 57
9 ADSS ADSS-1 ADSS 69 54 ADE12 70 51
10 AMPD AMPD-1 AMPD 72 59 AMD1 67 49
11 ADOD C06G3.5 ADA 58 40 - - -
12 ADOK R07H5.8 ADK 69 51 ADO1 60 43
13 APRT T19B4.3 APRT 65 46 APT1 61 43
14 PNP K02D7.1 PNP 64 47 PNP1 56 40
15 HGPRT HPRT-1 HPRT 62 49 HPT1 44 25
16 IMD T22D1.3 IMPDH 73 57 IMD1 66 46
17 GMPS GMPS-1 GMPS 65 51 GUA1 51 36
18 GDA CPIN-1 GDA 38 22 GUD1 37 21
19 XO GAD-3 XDH 50 35 - - -
19 XO F15E6.6 XDH 55 38 - - -
19 XO F55B11.1 XDH 61 47 - - -
60 70 80 90 100 11065 75 85 95 105
Ab
s 
26
0 
nm
 (a
.u
.)
ZM
P
G
uo
AM
P
In
os
in
e
C
D
P U
M
P
 
C
TP
 +
 A
D
P
IM
P 
+ 
U
D
P
G
M
P
AT
P
SZ
M
P
U
TP  
G
D
P+
SA
M
P
G
TP
 
sA
do
SA
IC
AR
Wild-type (mock RNAi)
Elution Time (min)
C
B
PRPP
SZMP
ZMP
IMPSAMPAMP XMP
Ade Hypox Gua
PRA
GAR
FGAR
FGAM
AIR
CAIR
GMP
Ado
Ino Xant
Guo
Uric Acid
GPPAT
ADSL
ATICADSL
PRPP
SZMP
IMPSAMPAMP XMP
Ade Hypox Gua
PRA
GAR
FGAR
FGAM
AIR
CAIR
GMP
Ado
Ino Xant
Guo
Uric Acid
GPPAT
ADSL
ATICADSL
PRPP
IMPSAMPAMP XMP
Ade Hypox Gua
GMP
Ado
Ino Xant
Guo
Uric Acid
GPPAT
ADSL
ATIC
ADSL
adsl-1(∆) atic-1(∆) ppat-1(∆)
Figure S1 - Purine biosynthesis pathway conservation in C. elegans. (A) Schematics of the 
Purine Biosynthesis pathways in C. elegans based on sequence homology, and table of 
comparison with both human and yeast (S. cerevisiae) orthologues. Enzymes subject to 
functional analysis are in red. (B) Schematics of predicted purine biosynthesis pathways in 
adsl-1(∆), atic-1(∆) and ppat-1(∆) mutants; large font represents intermediate metabolite 
accumulation. (C) Representative example of a chromatogram, absorbance at 260 nm, of 
wild-type worms, in mock (control) RNAi condition. 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PPAT-1
C. elegans---------------------------------------------------------MCGIFGIVAAGNYEHL---NVLAANGLAALQHRG-31
H. sapiens-----------------------------------------------MELEELGIREECGVFGCIASGEWPTQLDVPHVITLGLVGLQHRG-44
R. norvegicus-----------------------------------------------MELEESGIREECGVFGCIASGDWPTQLDVPHVITLGLVGLQHRG-44
D. melanogaster-MMAQSDSGNCCAKLNKDECCQKTKDVILSGVSPKMFPDKIYKSVQPKGEDATGMTCECGVFAAIACGDYPTQLDIAQMICLGLVALQHRG-90
S. cerevisiae---------------------------------------------------------MCGILGIVLANQTT---PVAPELCDGCIFLQHRG-31
C. elegans-TESTGLVGSDGITRDHVEIIKGHGLVRDVITEDNISRMNGQSIIIGHNRYSTAGKKKSGINCVQPFVVYTAMGTVAIAHNGELVDAKQKR-121
H. sapiens-QESAGIVTSDGSSVPTFKSHKGMGLVNHVFTEDNLKKLYVSNLGIGHTRYATTGKC--ELENCQPFVVETLHGKIAVAHNGELVNAARLR-132
R. norvegicus-QESAGIVTSDGSSVPKFRVHKGMGLVNHVFTEDNLKKLYVSNLGIGHTRYATTGKC--ELENCQPFVVETLHGKIAVAHNGELVNAARLR-132
D. melanogaster-QESAGIVTSLGKSSKNFSVHKGMGMINNLFNDEAIRKL-KGNLGIGHTRYSTAAAS--EVVNCQPFVVHTAHGALAIAHNGELVNCESLR-177
S. cerevisiae-QDAAGIATCGS--RGRIYQCKGNGMARDVFTQQRVSGL-AGSMGIAHLRYPTAGSS--ANSEAQPFYVNSPYG-INLAHNGNLVNTASLK-115
C. elegans-KEVLHE-GVGLSTDTDSELIAQMIAKAIALNVKCKYGQEMGDITRELAVTMSALNMSYSLL-VMTFDRLYAIRDPFGNRPLCVGTVYSK--208
H. sapiens-KKLLRH-GIGLSTSSDSEMITQLLAYTPPQ-E----QDDTPDWVARIKNLMKEAPTAYSLL-IMHRDVIYAVRDPYGNRPLCIGRLIPVS-215
R. norvegicus-KKLLRH-GIGLSTSSDSEMITQLLAYTPPQ-E----QDDTPDWVARIKNLMKEAPAAYSLV-IMHRDVIYAVRDPYGNRPLCIGRLMPVS-215
D. melanogaster-REVLER-GVGLSTHSDSELIAQSLCCAPEDVS----EHDGPNWPARIRHFMTLAPLSYSLV-VMHKDKIYAVRDSYGNRPLCLGKIVPVD-261
S. cerevisiae-RYMDEDVHRHINTDSDSELLLNIFAAELEKHN--KYRVNNEDVFHALEGVYRLCRGGYACVGLLAGFALFGFRDPNGIRPLLFGEREN---201
C. elegans---------NGNPEAFIASSESCAFPA-NAKLDFEVRPGEIVELSTGGIKSVWQ---MKPNTPLAMCIFEYVYFARNDSEIEGQQVQTVRE-286
H. sapiens-DINDKEKKTSETEGWVVSSESCSFLSIGARYYREVLPGEIVEISRHNVQTLDI-ISRSEGNPVAFCIFEYVYFARPDSMFEDQMVYTVRY-304
R. norvegicus-DINDKEKKSSETEGWVVSSESCSFLSIGARYCHEVKPGEIVEISRHGVRTLDI-IPRSNGDPVAFCIFEYVYFARPDSMFEDQMVYTVRY-304
D. melanogaster-AGH-ANINDQLAEGWVVSSESCGFLSIGARYVREVEPGEIIELSRNGYRTVDI-VERPDYKRMAFCIFEYVYFARSDSMFEGQMVYSARL-349
S. cerevisiae---------PDGTKDYMLASESVVFKAHNFTKYRDLKPGEAVIIPKNCSKGEPEFKQVVPINSYRPDLFEYVYFARPDSVLDGISVYHTRL-283
C. elegans-ECGKTMAL-----EDDLEADIVGNVPDSSLSAAIGYASQSGITYEPVLHRNSYVGRSFIEPNDEMRQNAIKMKFGVLKKKIHGQRIVLVD-371
H. sapiens-RCGQQLAI-----EAPVDADLVSTVPESATPAALAYAGKCGLPYVEVLCKNRYVGRTFIQPNMRLRQLGVAKKFGVLSDNFKGKRIVLVD-389
R. norvegicus-RCGQQLAV-----EAPVEADLVSTVPESATPAALGYATKCGLPYVEVLCKNRYVGRTFIQPNMRLRQLGVAKKFGVLSDNFKGKRIVLID-389
D. melanogaster-QCGRQLAR-----ESPLDADLVSSVPESGTAAAHGYARESGLPFGEVLCKNRYVGRTFIQPSTRLRQLGVAKKFGALAQNVEGKRIVLVD-434
S. cerevisiae-AMGSKLAENILKQLKPEDIDVVIPVPDTARTCALECANVLGKPYREGFVKNRYVGRTFIMPNQRERVSSVRRKLNPMESEFKGKKVLIVD-373
C. elegans-DSIVRGNTMRTLVKMLRDAGAKEVHLRIASPPVKFPCFMGINIPTTKELIAAEKTIPEICQFVGADSVRYLSVDGLVSSVQKGIER-----457
H. sapiens-DSIVRGNTISPIIKLLKESGAKEVHIRVASPPIKYPCFMGINIPTKEELIANKPEFDHLAEYLGANSVVYLSVEGLVSSVQEGIKFKKQK-479
R. norvegicus-DSIVRGNTISPIIKLLKESGAKEVHIRVASPPIKHPCFMGINIPTKEELIANKPEFEYLAEYLGANSVVYLSVEGLVSSVQQEIKFKKQK-479
D. melanogaster-DSIVRGNTIGPIIKLLRDAGATEVHIRIASPPLQYPCYMGINIPTREELIANKLNADQLADHVGADSLAYLSVEGLVKAVQMNKAH-----520
S. cerevisiae-DSIVRGTTSKEIVNMAKESGATKVYFASAAPAIRYNHIYGIDLTDTKNLIAYNRTDEEVAEVIGCERVIYQSLEDLIDCCKTDKITKFE--462
C. elegans----------------AANFSPGHCTACLTGKYPVAIDL---------------------------------- -480
H. sapiens-EKKHDIMIQENGNGLECFEKSGHCTACLTGKYPV----ELEW------------------------------ -517
R. norvegicus-VKKRDITIQENGNGLEYFEKTGHCTACLTGQYPV----DLEW------------------------------ -517
D. melanogaster----------------VNPLKAGYCTACLTGEYPGGLPEELSW------------------------------ -547
S. cerevisiae-------------------------DGVFTGNYVTGVEDGYIQELEEKRESIANNSSDMKAEVDIGLYNCADY -510
ADSL-1
C. elegans-------MASEDKFESVLSTRYCKNSPLVSILSETNKATLWRQLWIWLAEAEKELGLKQVTQDAIDEMKSNRDV--FDWPFIRSEERKLKH-82
H. sapiens-MAAGGDHGSPDSYRSPLASRYASP-EMCFVFSDRYKFRTWRQLWLWLAEAEQTLGLPIT-DEQIQEMKSNLEN--IDFKMAAEEEKRLRH-86
R. norvegicus-MAASGDPACAESYRSPLAARYASH-EMCFLFSDRYKFQTWRQLWLWLAEAEQTLGLPIT-DEQIQEMRSNLSN--IDFQMAAEEEKRLRH-86
D. melanogaster------MASNYEGYKSPLSTRYASK-EMQFLFSDQNKFSTWRRLWVWLAKAESRLGLEIS-DAQIAEMELQISN--IDFEAAAAEERLTRH-81
S. cerevisiae-------MPDYDNYTTPLSSRYASK-EMSATFSLRNRFSTWRKLWLNLAIAEKELGLTVVTDEAIEQMRKHVEITDDEIAKASAQEAIVRH-83
C. elegans-DVMAHNHAFGKLCPTAAGIIHLGATSCFVQDNADLIAYRDSIDHILKRFATVIDRLAAFSLKNKEVVTVGRTHYQTASLVTVGKRGVLWA-172
H. sapiens-DVMAHVHTFGHCCPKAAGIIHLGATSCYVGDNTDLIILRNALDLLLPKLARVISRLADFAKERASLPTLGFTHFQPAQLTTVGKRCCLWI-176
R. norvegicus-DVMAHVHTFGHCCPKAAGIIHLGATSCYVGDNTDLIILRNAFDLLLPKLARVISRLADFAKERADLPTLGFTHFQPAQLTTVGKRCCLWI-176
D. melanogaster-DVMAHVHVFAKQCPSAAPVIHLGATSCYVGDNTDLIVLRDALKLLLPRVASVIARLSQFAQSYKDQPTLGFTHLQPAQLTTVGKRACLWI-171
S. cerevisiae-DVMAHVHTFGETCPAAAGIIHLGATSCFVTDNADLIFIRDAYDIIIPKLVNVINRLAKFAMEYKDLPVLGWTHFQPAQLTTLGKRATLWI-173
C. elegans-QELLMAFQSLSEFRDKMRFRGIKGATGTQDSFLTLFAGDESKVEALDELVTKKANFSNRFLITGQTYSRQQDSQLVFSLSLLGAAAKKVC-262
H. sapiens-QDLCMDLQNLKRVRDDLRFRGVKGTTGTQASFLQLFEGDDHKVEQLDKMVTEKAGFKRAFIITGQTYTRKVDIEVLSVLASLGASVHKIC-266
R. norvegicus-QDLCMDLQNLKRVRDELRFRGVKGTTGTQASFLQLFEGDHQKVEQLDKMVTEKAGFKRAYIITGQTYTRKVDIEVLSVLASLGASVHKIC-266
D. melanogaster-QDLIMDERALSRCLEDLRFRGVKGTTGTQASFLQLFNGDGEKVKQLDQLVTELAGFKKAYAVTGQTYSRKVDVEIVAALASLGTTIHKMC-261
S. cerevisiae-QELLWDLRNFERARNDIGLRGVKGTTGTQASFLALFHGNHDKVEALDERVTELLGFDKVYPVTGQTYSRKIDIDVLAPLSSFAATAHKMA-263
C. elegans-TDIRVLQAFGELLEPFEKDQIGSSAMPYKKNPMKSERCCALSRKLINAPQEALTILADQGLERTLDDSAGRRMLIPDVLLTAEALLTTLQ-352
H. sapiens-TDIRLLANLKEMEEPFEKQQIGSSAMPYKRNPMRSERCCSLARHLMTLVMDPLQTASVQWFERTLDDSANRRICLAEAFLTADTILNTLQ-356
R. norvegicus-TDIRLLANLKEMEEPFEKQQIGSSAMPYKRNPMRSERCCSLARHLMSLTMDPLQTASVQWFERTLDDSANRRICLAEAFLTADTILTTLQ-356
D. melanogaster-SDLRILASRKELEEPFESTQIGSSAMPYKRNPMRSERCCALARHLITLFSSAANTHATQWLERTLDDSANRRLTLSEAFLAADAALLTLL-351
S. cerevisiae-TDIRLLANLKEVEEPFEKSQIGSSAMAYKRNPMRCERVCSLARHLGSLFSDAVQTASVQWFERTLDDSAIRRISLPSAFLTADILLSTLL-353
C. elegans-NIFEGLSVQTDNVKKIVEDEIAFLGLEKAMMMLTEEGVDRQQAHAVIRKTALEAKQLQA---TQKVDIRQTMADPFFDSVRDRVVGLVNN-439
H. sapiens-NISEGLVVYPKVIERRIRQELPFMATENIIMAMVKAGGSRQDCHEKIRVLSQQAASVVKQEGGDNDLIERIQVDAYFSPIHSQLDH-LLD-445
R. norvegicus-NVSEGLVLYPKVIERRIRQELPFMATENIIMAMVKAGGSRQDCHEKIRVLSQQAAAVVKQEGGDNDLIERIRADAYFSPIHSQLEQ-LLD-445
D. melanogaster-NISQGLVVYPKVIERHISQELPFMSTENIIMAMVKAGGDRQVCHEKIRVLSQEAGAQVKQHGKDNDLVVRVRKDPYFSPILEQLDT-ILD-440
S. cerevisiae-NISSGLVVYPKVIERRIKGELPFMATENIIMAMVEKNASRQEVHERIRVLSHQAAAVVKEEGGENDLIERVKRDEFFKPIWEELDS-LLE-442
C. elegans-PINFTGRCVSQTESFIAKELKPTIDKYLDKSAGNVQL--DV -478
H. sapiens-PSSFTGRASQQVQRFLEEEVYPLLKPYESVMKVKAELCL-- -484
R. norvegicus-PSSFTGRAPQQVHRFLEEEVYPLLKPYGSVMAVKAELCL-- -484
D. melanogaster-AKTFTGRASDQVGEFVKEEVEPVLARYSEALKNVQDVKLNI -481
S. cerevisiae-PSTFVGRAPQQVEKFVQKDVNNALQPFQKYLNDE-QVKLNV -482
ATIC-1
C. elegans-MTDGKSLAIISVSDKTGLIPLAHGLVSAGLTLIASGGTAKAIRDQGIDVHDVADVTKFPEMLGGRVKTLHPAVHGGILARDTESDRKDLE-90
H. sapiens--MAPGQLALFSVSDKTGLVEFARNLTALGLNLVASGGTAKALRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPEDNADMA-89
R. norvegicus--MASSQLALFSVSDKTGLVEFARNLASLGLSLVASGGTAKAIRDAGLAVRDVSELTGFPEMLGGRVKTLHPAVHAGILARNIPEDAADMA-89
D. melanogaster--MSSSKIALLSVSDKTGLLDLGKSLVALGFDLVASGGTATSLRGAGLKVRDVSEITGAPEMLGGRVKTLHPAVHAGILSRTTDSDLADMR-89
S. cerevisiae-MANYTKTAILSVYDKTGLLDLARGLIEKNVRILASGGTARMIRDAGFPIEDVSAITHAPEMLGGRVKTLHPAVHGGILARDIDSDEKDLK-90
C. elegans-KHNISFVSVVVCNLYPFKKTVQSKDCSVEEAVENIDIGGVTLLRAAAKNHERVSVICDPADYDHIISELKSG---GTTRERRQLLALKAF-177
H. sapiens-RLDFNLIRVVACNLYPFVKTVASPGVTVEEAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYVVVSTEMQSSESKDTSLETRRQLALKAF-179
R. norvegicus-RLDFNLIRVVVCNLYPFVKTVASPDVTVEAAVEQIDIGGVTLLRAAAKNHARVTVVCEPEDYGAVAAEMQGSGNKDTSLETRRHLALKAF-179
D. melanogaster-KQGFDLIQLVVCNLYPFASTVAKPDVTLADAVENIDIGGVTLLRAAAKNHQRVTVVCEAVDYDRVLSELKAS--GNTTVETRQALALKAF-177
S. cerevisiae-EQHIEKVDYVVCNLYPFKETVAKVGVTIPEAVEEIDIGGVTLLRAAAKNHARVTILSDPKDYSEFLSELSSN--GEISQDLRNRLALKAF-178
C. elegans-EHTTSYDESISGFMRRRFAGNGERALPLRYGTNPHQKDDAELYIVEDEMPIKVLNGSPGYINILDGLNGWQLVKELSDATKMPAAASFKH-267
H. sapiens-THTAQYDEAISDYFRKQY-SKGVSQMPLRYGMNPHQTPAQLYT-LQPKLPITVLNGAPGFINLCDALNAWQLVKELKEALGIPAAASFKH-267
R. norvegicus-THTAQYDEAISDYFRRQY-SKGISQMPLRYGMNPHQTPAQLYT-LKPKLPITVLNGAPGFINLCDALNAWQLVTELRGAVDIPAAASFKH-267
D. melanogaster-THTATYDDAISDYFRKQY-GSGVSQLPLRYGMNPHQKPAQLYT-QLAKLPLTVLNASPGFINLCDALNGWQLVRELKKALQLPAATSFKH-265
S. cerevisiae-EHTADYDAAISDFFRKQY-SEGQAQITLRYGANPHQKPAQAYVSQQDSLPFKVLCGSPGYINLLDALNSWPLVKELSASLNLPAAASFKH-267
C. elegans-VSPAGAAVGLPLNETEAACCMVSDLPIDTKKPSLAAAYARARGADRMSSFGDFIALSEKCDELTAKIINREVSDGVVAPDFDPAALSLLA-357
H. sapiens-VSPAGAAVGIPLSEDEAKVCMVYDLYK--TLTPISAAYARARGADRMSSFGDFVALSDVCDVPTAKIISREVSDGIIAPGYEEEALTILS-355
R. norvegicus-VSPAGAAVGVPLSEDEARVCMVYDLYP--TLTPLAIAYARARGADRMSSFGDFVALSDVCDVPTAKIISREVSDGIVAPGYEEEALKILS-355
D. melanogaster-VSPAGAAVGVPLNPAQAKLCMVDDLYE--QLTPLATAYARARGADRMSSFGDFVALSDVCDVVTARIISREVSDGIIAAGYEPEALEILK-353
S. cerevisiae-VSPAGAAVGIPLSDVEKQVYFVADI-E--NLSPLACAYARARGADRMSSFGDWIALSNIVDVPTAKIISREVSDGVIAPGYEPEALAILS-354
C. elegans-KKKNGNYCVLKINPNYLPSETEERTVFGLRLRQKRNNAVINAETFNNVVGSANELNKQAIDDLIVATIALKYAQSNSVCFAHRGQVIGMG-447
H. sapiens-KKKNGNYCVLQMDQSYKPDENEVRTLFGLHLSQKRNNGVVDKSLFSNVVTKNKDLPESALRDLIVATIAVKYTQSNSVCYAKNGQVIGIG-445
R. norvegicus-KKKNGSYCVLQMDQSYKPDENEVRTLFGLRLSQKRNNGVVDKSLFSNIVTKNKDLPESALRDLIVATIAVKYTQSNSVCYAKDGQVIGIG-445
D. melanogaster-KKKNGGYCILQMDPNYEPSAVERKTIFGLTLEQKRNDAVIDASLFSNVVSKRGPLPEVAVRDLIVATIALKYTQSNSVCYARDGQVVGIG-443
S. cerevisiae-KKKGGKYCILQIDPNYVPEAVERRQVYGVTLEQKRNDAIINQSTFKEIVSQNKNLTEQAIIDLTVATIAIKYTQSNSVCYARNGMVVGLG-444
C. elegans-AGQQSRIHCTRLAGDKAMNWWLRQHPTVLSLPWKNAIKRSEKSNAIDVLCSGVLGSEI-AIDQWQQYFNEPVEPLAEDDRKQWLSQQTGV-536
H. sapiens-AGQQSRIHCTRLAGDKANYWWLRHHPQVLSMKFKTGVKRAEISNAIDQYVTGTIGEDE-DLIKWKALFEEVPELLTEAEKKEWVEKLTEV-534
R. norvegicus-AGQQSRIHCTRLAGDKANSWWLRHHPRVLSMKFKAGVKRAEVSNAIDQYVTGTIGEGE-DLVKWKALFEEVPELLTEAEKKEWVDKLSGV-534
D. melanogaster-AGQQSRIHCTRLAGEKADNWWLRQHPSVAGMKFKAGVKRAEISNAIDNYVNGTVGKDM-PLSQFEGMFDKAPAQLTSEQKVEWLKQLSGV-532
S. cerevisiae-AGQQSRIHCTRLAGDKADNWWFRQHPRVLEIKWAKGVKRPEKSNAIDLFVTGQIPTEEPELSEYQSKFEEIPKPFTPEERKEWLSKLTNV-534
C. elegans-VMSSDAFLPFRDNVDCAKQFGVSYVAHPGGSVRDDDIKEACDEHGITLIHTGLRLFHH -594
H. sapiens-SISSDAFFPFRDNVDRAKRSGVAYIAAPSGSAADKVVIEACDELGIILAHTNLRLFHH -592
R. norvegicus-SVSSDAFFPFRDNVDRAKRSGVAYIVAPSGSTADKVVIEACDELGIVLAHTDLRLFHH -592
D. melanogaster-ALGSDAFFPFRDNIDRASLSGVSYIASPAGSTNDAGVIAACDEHGIIMAHTNLRLFHH -590
S. cerevisiae-SLSSDAFFPFPDNVYRAVKSGVKYIAAPSGSVMDKVVFSAADSFDLVYVENPIRLFHH -592
Figure S2 - Sequence alignment of C. elegans PPAT-1, ADSL-1 and ATIC-1 with closest 
orthologue in humans, rat (Rattus norvegicus), fly (Drosophila melanogaster) and yeast (S. 
cerevisiae). Grey boxes indicate similar residues, black boxes indicate identical residues.
Figure S3
Figure S3 - Developmental defects in purine mutants. (A) Representative DIC micrographs 
of the vulva region in young adults of wild-type, ppat-1(∆), adsl-1(∆) and ppat-1(∆); 
adsl-1(∆) genotypes (bar= 20µm). (B) Graph depicting the average number of eggs laid by 
the de novo pathway mutants, and AICAR treated ppat-1(∆); atic-1(∆) (0.1 mM) and wild-
type (0.5 mM) worms (error bar - standard error of the mean; n= 30 in all samples; * - 
statistically significant difference relative to wild-type - Student’s t-test). (C) Graph 
displaying the percentage of embryonic lethality (unhatched eggs) upon adsl-1(RNAi) and 
mock (control) RNAi in both wild-type and ppat-1(∆). 
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Figure S4 - Post-embryonic development in purine mutants. (A) Representative 
bioluminescence profiles of a single wild-type (left, blue line) and adsl-1(∆) mutant (right, 
orange line) individuals over time. Arrows indicate drop in luminescence observed during 
lethargus phase. (B) Detailed representation of the primary data presented in figure 3A, 
each circle corresponds to an individual observation, bars indicate median, 2nd and 3rd 
quartiles. L1 through L4 refer to the four larval stages and M1 though M4 refer to the 
lethargus phases following each larval stage. For better visualization adsl-1(∆) and 
ppat-1(∆); adsl-1(∆) in L3, L4, M3 and M4 are represented on a different time scale. (* - 
statistically significant difference compared to wild-type; one-way ANOVA). 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Figure S5
Figure S5 - AICAR treatment and locomotion. (A) Graph depicting the average locomotion 
speed in de novo pathway mutants treated with AICAR (error bar - standard error of the 
mean; n= 30 in ppat-1(∆) and atic-1(∆), n= 40 in wild-type and ppat-1(∆); atic-1(∆); * - 
statistically significant difference relative to wild-type - Student’s t-test). (B) Zoom in on 
HPLC chromatogram peaks of specific metabolites AICAR, ZMP, SAICAR, SZMP, ZTP, 
uric acid, ATP and GTP, upon 0.5 mM AICAR treatment. (C) Zoom in on HPLC 
chromatogram peaks of ZMP upon 0.5 mM AICAR treatment, with the four genotypes 
analyzed represented on the sale scale. 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Figure S6
Figure S6 - Neuromuscular function in purine mutants. (A) Percentage of paralysed worms 
upon Aldicarb treatment, in all studied genotypes (wild-type n= 136, ppat-1(∆) n= 169, 
atic-1(∆) n= 178, ppat-1(∆); atic-1(∆) n= 140, adsl-1(∆) n= 54, ppat-1(∆); adsl-1(∆) n= 65). 
(B) Percentage of paralysed worms upon Levamisole treatment, in all studied genotypes 
(wild-type n= 50, ppat-1(∆) n= 49, atic-1(∆) n= 51, ppat-1(∆); atic-1(∆) n= 50, adsl-1(∆) n= 
104, ppat-1(∆); adsl-1(∆) n= 54). (C) Graph presenting the percentage of observed 
responses to mechanosensorial stimulation in all studied genotypes (wild-type n= 30, 
ppat-1(∆) n= 30, atic-1(∆) n= 30, ppat-1(∆); atic-1(∆) n= 30, adsl-1(∆) n= 30, ppat-1(∆); 
adsl-1(∆) n= 30).
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